• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months

    9/22/25 8:45:00 AM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACTU alert in real time by email
    • Elraglusib represents a potential back bone therapy in pancreatic cancer with three ongoing trials in combination with current standards of care and novel immunotherapies
    • Recent financing provides extended runway through key anticipated regulatory inflection points
    • Additional nonclinical studies are ongoing combining elraglusib with RAS inhibitors based on potential synergies and complimentary mechanisms of action

    CHICAGO and FORT WORTH, Texas, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced a corporate update on the regulatory path for elraglusib in pancreatic cancer and anticipated milestones enabled by the recent $17.25 million public offering.

    Actuate has amended its investigational new drug (IND) application with updated clinical data from its international randomized Phase 2 trial in first-line treatment of metastatic pancreatic cancer (Actuate-1801 Part 3B), which showed a statistically significant improvement in median overall survival with the combination arm of elraglusib plus gemcitabine/nab-paclitaxel (GnP) versus GnP alone. These data are intended to support planned regulatory submissions with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) beginning later this year and continuing into early 2026.

    The 1801-3B Phase 2 study is currently ongoing, with 22 patients in the elraglusib plus GnP arm either in active treatment or survival follow-up, ranging from 20 to 42 months in time on study, while only 3 patients remain in survival follow-up in the GnP arm, with time on study ranging from 21 to 23 months.

    These compelling results of elraglusib in combination with GnP, combined with early data demonstrating significant and durable long term responses in patients with highly metastatic disease treated with the combination of elraglusib/FOLFIRINOX/losartan in the ongoing clinical trial in patients with mPDAC led by Havard/MGH, plus the new clinical collaboration with Incyte and UPMC Hillman Cancer Center in patients with advanced pancreatic cancer using the combination of modified FOLFIRINOX and Incyte's anti-PD-1 retifanlimab, further strengthen the case for elraglusib as a back-bone therapy that can be combined with different regimens used to treat this highly aggressive and deadly disease.

    "We are confident that our recently completed financing provides sufficient capital to support our corporate initiatives into the second half of 2026, and well through our upcoming anticipated interactions with the FDA and EMA. We have already updated the clinical data package on file with the FDA, and during the remainder of this year and into the first quarter of 2026, we expect to gain clarity on elraglusib's regulatory path forward for the first-line treatment of metastatic PDAC," said Daniel Schmitt, President & Chief Executive Officer of Actuate. "The survival benefit we've observed with elraglusib to date is compelling, and both its mechanism of action and safety profile support combination with chemotherapy, immunotherapy and potentially RAS inhibitors, increasing elraglusib's potential as a backbone therapy, specifically in pancreatic cancers, where clinicians have limited options to extend and improve the lives of patients."

    About Actuate-1801 Part 3β Study

    The Actuate-1801 Part 3β study (NCT03678883) is a randomized, controlled Phase 2 trial of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) versus GnP alone in first-line metastatic pancreatic adenocarcinoma (mPDAC). The trial enrolled 286 mPDAC patients with no prior systemic treatment for metastatic disease, who were randomized 2:1 to the elraglusib treatment arm (elraglusib + GnP) or the control arm (GnP alone). Elraglusib is administered at a dose of 9.3 mg/kg by IV infusion on Day 1 of each week of a 28-day cycle.

    In the Phase 2 study, elraglusib in combination with GnP met its primary endpoint, showing a significant increase in median overall survival, a 37% reduction in the risk of death, and a doubling of the 12-month survival rate. In addition, increased CD8-positive and granzyme B-positive T cells, increased NK cells, and decreased myeloid-derived suppressor cells were observed in tumor biopsies only from elraglusib-treated patients, demonstrating elraglusib's proposed immune modulating mechanism of action in patients with mPDAC.

    Inhibition of GSK-3β may inhibit pancreatic tumor growth and improve survival through several complimentary mechanisms that include enhancement of chemotherapy activity, regulation of anti-tumor immunity, and regulation of tumor gene expression, leading to alterations in tumor metabolism and Epithelial-to-Mesenchymal Transition (EMT).

    About Actuate Therapeutics, Inc.

    Actuate is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers. Actuate's lead investigational drug, elraglusib (a novel GSK-3β inhibitor), targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as chemotherapy through the inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and DNA Damage Response (DDR). Elraglusib may also mediate anti-tumor immunity through the regulation of multiple immune checkpoints and immune cell function.

    For additional information, please visit the Company's website at http://www.actuatetherapeutics.com or follow us on LinkedIn, X and Facebook.

    Forward-Looking Statements

    This press release contains forward-looking statements about us, including our and other parties' clinical trials and development plans, and our industry. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "ongoing," "plan," "potential," "predict," "project," "should," "target," "will," "would," or the negative of these terms or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. All statements, other than statements related to present facts or current conditions or of historical facts, contained in this press release are forward-looking statements. Accordingly, these statements involve estimates, assumptions, substantial risks and uncertainties which could cause actual results to differ materially from those expressed in them, including but not limited to that preliminary and unpublished data may be subject to change and further interpretation following the availability of more data or following a more comprehensive review of the data and should not be relied upon as a final analysis; clinical and preclinical drug development involves a lengthy and expensive process with uncertain timelines and outcomes, results of prior preclinical studies, early clinical trials and sub-group studies are not necessarily predictive of future results and may not correlate with improved responses, and elraglusib may not achieve positive clinical results or favorable preclinical results or receive regulatory approval on a timely basis, if at all; that we may not successfully enroll additional patients or establish or advance plans for further development, including through conversations with the FDA or EMA and the standards such bodies may impose for such development; that elraglusib could be associated with side effects, adverse events or other properties or safety risks, which could delay or preclude regulatory approval, cause us to suspend or discontinue clinical trials or result in other negative consequences; our reliance on third parties to conduct our non-clinical studies and our clinical trials; our reliance on third-party licensors and ability to preserve and protect our intellectual property rights; that we face significant competition from other biotechnology and pharmaceutical companies; our ability to fund development activities, including because our financial condition raises substantial doubt as to our ability to continue as a going concern and we require additional capital to finance our operations beyond the second quarter of fiscal year 2026, and a failure to obtain this necessary capital in the near term on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our development programs, commercialization efforts or other operations. In addition, any forward-looking statements are qualified in their entirety by reference to the factors discussed under the heading "Item 1A. Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 13, 2025, and our Quarterly Reports on Form 10-Q, and other filings with the SEC. Because the risk factors referred to above could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Unless legally required, we do not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

    Investor Contact

    Mike Moyer

    Managing Director

    LifeSci Advisors, LLC

    [email protected]

    Media Contact

    Ignacio Guerrero-Ros, Ph.D., or David Schull

    Russo Partners, LLC

    [email protected]

    [email protected]

    (858) 717-2310 or (646) 942-5604



    Primary Logo

    Get the next $ACTU alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACTU

    DatePrice TargetRatingAnalyst
    8/26/2025$20.00Buy
    B. Riley Securities
    4/22/2025$21.00Buy
    Craig Hallum
    3/17/2025$20.00Buy
    H.C. Wainwright
    More analyst ratings

    $ACTU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bios Equity Cof, Lp bought $499,996 worth of shares (71,428 units at $7.00) (SEC Form 4)

    4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

    6/30/25 1:03:52 PM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Kreis Leslie W. bought $499,996 worth of shares (71,428 units at $7.00) (SEC Form 4)

    4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

    6/30/25 1:02:42 PM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Fletcher Aaron G.L. bought $499,996 worth of shares (71,428 units at $7.00) (SEC Form 4)

    4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

    6/30/25 1:01:13 PM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACTU
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months

    Elraglusib represents a potential back bone therapy in pancreatic cancer with three ongoing trials in combination with current standards of care and novel immunotherapiesRecent financing provides extended runway through key anticipated regulatory inflection pointsAdditional nonclinical studies are ongoing combining elraglusib with RAS inhibitors based on potential synergies and complimentary mechanisms of action CHICAGO and FORT WORTH, Texas, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through

    9/22/25 8:45:00 AM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Actuate Therapeutics Announces Closing of $17.25 Million Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option

    CHICAGO and FORT WORTH, Texas, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced the closing of its $17.25 million underwritten public offering of 2,464,286 shares of its common stock, including 321,428 additional shares of its common stock issued pursuant to the full exercise by the underwriter of its over-allotment option. The public offering price, before underwriting discounts and commissions, for each share of com

    9/11/25 4:01:00 PM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock

    CHICAGO and FORT WORTH, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that it has priced an underwritten public offering of 2,142,858 shares of its common stock at an offering price of $7.00 per share of common stock. Actuate has granted the underwriters a 30-day option to purchase up to 321,428 additional shares of its common stock sold in the offering at the public offering price per share, less underwriti

    9/10/25 8:31:02 AM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACTU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on Actuate Therapeutics with a new price target

    B. Riley Securities initiated coverage of Actuate Therapeutics with a rating of Buy and set a new price target of $20.00

    8/26/25 8:17:26 AM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Craig Hallum initiated coverage on Actuate Therapeutics with a new price target

    Craig Hallum initiated coverage of Actuate Therapeutics with a rating of Buy and set a new price target of $21.00

    4/22/25 8:00:39 AM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Actuate Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Actuate Therapeutics with a rating of Buy and set a new price target of $20.00

    3/17/25 7:17:09 AM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACTU
    SEC Filings

    View All

    Actuate Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)

    9/10/25 5:11:14 PM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Actuate Therapeutics Inc.

    424B5 - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)

    9/10/25 5:05:01 PM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Actuate Therapeutics Inc.

    424B5 - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)

    9/9/25 4:01:38 PM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACTU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bios Equity Cof, Lp bought $499,996 worth of shares (71,428 units at $7.00) (SEC Form 4)

    4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

    6/30/25 1:03:52 PM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Kreis Leslie W. bought $499,996 worth of shares (71,428 units at $7.00) (SEC Form 4)

    4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

    6/30/25 1:02:42 PM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Fletcher Aaron G.L. bought $499,996 worth of shares (71,428 units at $7.00) (SEC Form 4)

    4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

    6/30/25 1:01:13 PM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACTU
    Financials

    Live finance-specific insights

    View All

    Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results

    HARMONIC™ trial lead-in cohort delivered impressive 86% clinical benefit rate and 43% objective response rate in never-smoker NSCLC patients, with current expansion cohort reinforcing these positive trends as enrollment accelerates in Japan and Taiwan, where 33-40% of NSCLC cases occur in never-smokers, positioning Lantern for multiple clinical readouts in 2025. LP-184 received two U.S. FDA Fast Track Designations in 2024 for Glioblastoma and Triple Negative Breast Cancer, plus three additional Rare Pediatric Disease Designations, strengthening future market potential across multiple high-need indications with multi billion U.S. dollar market potential. Successfully dosed multiple pati

    3/27/25 4:01:00 PM ET
    $ACTU
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACTU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Actuate Therapeutics Inc.

    SC 13D - ACTUATE THERAPEUTICS, INC. (0001652935) (Subject)

    8/19/24 8:59:59 PM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care